ASIA PACIFIC GENERIC ONCOLOGY STERILE INJECTABLE MARKET ANALYSIS

Asia Pacific Generic Oncology Sterile Injectable Market, by Drug Type (Monoclonal Antibodies, Chemotherapy (Alkylating Agents, Antimetabolites, Plant Alkaloids, Antitumor Antibiotics, and Others), Cytokines, and Peptide Hormones), by Disease Indication (Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Country (China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Published In : Dec 2021
Code : CMI4839
Pages :181
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Asia Pacific Generic Oncology Sterile Injectable Market – Restraints

Shortage of supply for various important generic drugs, especially the injectable form of drugs that are primarily used in cancer chemotherapy, is a major problem faced globally. Due to consistent shortage, patients are unable to gain access to basic life-saving drugs and this shortage is expected to severely affect the growth of the market.

The reasons for the shortage of drugs are increasing manufacturing issues such as introduction of particulate matter in the vials, equipment failures, and fungal or bacterial contaminations, delay in supply due to unavailability of raw material to start drug manufacture, and shortage of active pharmaceutical ingredients (API). Low availability of raw materials is one of the major issues, which is expected to adversely affect the growth of Asia Pacific oncology sterile injectable market.

Patent expiry of biologics is a major factor that is expected to drive the market growth over the forecast period